Drug Trial Radar · NCT06160895
A Clinical Trial of TQ-A3334 Tablet After Multiple Administration in Adult Subjects
Last checked: Nov 19, 2026Latest source record: Oct 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Dec 26, 2023
Primary completion
Jun 24, 2024
Study completion Aug 19, 2024
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a randomized, double-blind, placebo-controlled Phase I clinical study of TQ-A3334 tablets in adult healthy subjects, and the trial is planned to enroll 60 healthy subjects. The primary objective is to evaluate the safety and tolerability of multiple dosing of TQ-A3334 tablets in healthy subjects.
Conditions
- Hepatitis B
Interventions
TQ-A3334 tabletsDrug
TQ-A3334 tablet is a Toll like receptor 7 (TLR7) agonist.
TQ-A3334 placebo tabletsDrug
TQ-A3334 placebo tablet is a placebo that has no effect on TLR7.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AE)Time frame: From patient enrollment to withdrawal, estimated to be around 1 month.
- Severity of adverse events (AE)Time frame: From patient enrollment to withdrawal, estimated to be around 1 month.
- Incidence of serious adverse events (SAE)Time frame: From patient enrollment to withdrawal, estimated to be around 1 month.
- Severity of serious adverse events (SAE)Time frame: From patient enrollment to withdrawal, estimated to be around 1 month.
- Tolerability after drug administrationTime frame: From patient enrollment to withdrawal, estimated to be around 1 month.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The first hospital of Jilin University
Changchun, Jilin, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.